Recognition of bacterial products by toll-like receptors

Chemical Immunology and Allergy

Volumn 86, Issue , 2005, Pages 99-119

  Heine, Holger ^a,b   Ulmer, Artur J ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b Research Center Borstel   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; BACTERIAL DNA; BETA DEFENSIN; FLAGELLIN; GLYCOLIPID; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEPARAN SULFATE; IMIQUIMOD; LIPID A; LIPOARABINOMANNAN; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; PEPTIDOGLYCAN; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG; ZYMOSAN;

ANTIGEN RECOGNITION; ASPERGILLUS FUMIGATUS; CRYPTOCOCCUS; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNITY; LEGIONELLA PNEUMOPHILA; LEPTOSPIRA INTERROGANS; MAMMAL CELL; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PORPHYROMONAS GINGIVALIS; PREVOTELLA INTERMEDIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROVIRUS; REVIEW; SIGNAL TRANSDUCTION; SPIROCHETE; STREPTOCOCCUS AGALACTIAE; TREPONEMA; TRYPANOSOMA CRUZI; YERSINIA ENTEROCOLITICA;

EID: 21344458844     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000086654     Document Type: Review

References (165)

1. Janeway CA Jr: Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54:1-13.
2. Kirschning CJ, Wesche H, Merrill AT, Rothe M: Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998;188:2091-2097.
3. Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang M, Goddard A, Wood WI, Gurney AL, Godowski PJ: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998;395:284-288.
4. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ: Cutting edge: Repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol 2000;165:618-622.
5. Lee HK, Lee J, Tobias PS: Two lipoproteins extracted from Escherichia coli K-12 LCD25 lipopolysaccharide are the major components responsible for Toll-like receptor 2-mediated signaling. J Immunol 2002;168:4012-4017.
6. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 1999;162:3749-3752.
7. Heine H, Kirschning CJ, Lien E, Monks BG, Rothe M, Golenbock DT: Cutting edge: Cells that carry A null allele for toll-like receptor 2 are capable of responding to endotoxin. J Immunol 1999;162:6971-6975.
8. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-451.
9. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999;189: 1777-1782.
10. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, Miyake K: Cutting edge: Cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol 2000;164:3471-3475.
11. Visintin A, Mazzoni A, Spitzer JA, Segal DM: Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci USA 2001;98:12156-12161.
12. Yang H, Young DW, Gusovsky F, Chow JC: Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem 2000;275:20861-20866.
13. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN: MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001;276:38044-38051.
14. Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, Heine H, Latz E, Monks BG, Schwartz DA, Miyake K, Golenbock DT: Molecular genetic analysis of an endotoxin non-responder mutant cell line: A point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med 2001;194:79-88.
15. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-787.
16. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide binding protein. Science 1990;249:1429-1431.
17. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein [see comments]. Science 1990;249: 1431-1433.
18. Kirkland TN, Finley F, Leturcq D, Moriarty A, Lee JD, Ulevitch RJ, Tobias PS: Analysis of lipopolysaccharide binding by CD14. J Biol Chem 1993;268:24818-24823.
19. Schromm AB, Brandenburg K, Rietschel ET, Flad HD, Carroll SF, Seydel U: Lipopolysaccharide-binding protein mediates CD14-independent intercalation of lipopolysaccharide into phospholipid membranes. FEBS Lett 1996;399:267-271.
20. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT: Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000;105:497-504.
21. Poltorak A, Ricciardi-Castagnoli P, Citterio S, Beutler B: Physical contact between lipopolysaccharide and Toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci USA 2000;97:2163-2167.
22. da Silva CJ, Soldau K, Christen U, Tobias PS, Ulevitch RJ: Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex: Transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001;276:21129-21135.
23. Akashi S, Saitoh S, Wakabayashi Y, Kikuchi T, Takamura N, Nagai Y, Kusumoto Y, Fukase K, Kusumoto S, Adachi Y, Kosugi A, Miyake K: Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: Higher affinity than that with MD-2 or CD14. J Exp Med 2003; 198:1035-1042.
24. Visintin A, Latz E, Monks BG, Espevik T, Golenbock DT: Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem 2003;278:48313-48320.
25. Kennedy MN, Mullen GE, Leifer CA, Lee C, Mazzoni A, Dileepan KN, Segal DM: A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem 2004;279:34698-34704.
26. Fujimoto T, Yamazaki S, Eto-Kimura A, Takeshige K, Muta T: The amino-terminal region of toll-like receptor 4 is essential for binding to MD-2 and receptor translocation to the cell surface. J Biol Chem 2004;279:47431- 47437.
27. Lüderitz O, Freudenberg M, Galanos C, Lehmann V, Rietschel ET, Shaw D: Lipopolysaccharides of gram-negative bacteria; in Razin S, Rottern S (eds): Current Topics in Membrane and Transport. New York, Academic Press, 1982, pp 79-151.
28. Galanos C, Lüderitz O, Rietschel ETh, Westphal O, Brade H, Brade L, Freudenberg MA, Schade UF, Imoto M, Yoshimura H, Kusumoto S, Shiba T: Synthetic and Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 1985;148:1-5.
29. Feist W, Ulmer AJ, Musehold J, Brade H, Kusumoto S, Flad HD: Induction of tumor necrosis factor-alpha release by lipopolysaccharide and defined lipopolysaccharide partial structures. Immunobiology 1989;179:293-307.
30. Rietschel ET, Brade L, Brandenburg K, Flad HD, de Jong-Leuveninck J, Kawahara K, Lindner B, Loppnow H, Luderitz T, Schade U: Chemical structure and biologic activity of bacterial and synthetic lipid A. Rev Infect Dis 1987;9(suppl 5):S527-S536.
31. Rietschel ET, Brade L, Schade FU, Seydel U, Zahringer U, Kusumoto S, Brade H: Bacterial endotoxins: Properties and structure of biologically active domains; in Schrinner E, Richmont MH, Seibert G, Schwarz U (eds): Surface of Microorganisms and Their Interactions with the Mammalian Host. Weinheim, Verlag Chemie, 1988, pp 1-41.
32. Wang M-H, Chen Y-Q, Flad H-D, Baer HH, Feist W, Ulmer AJ: Inhibition of interleukin-6 release and T-cell proliferation by synthetic mirror pseudo cord factor analogues in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol 1993;6:53-62.
33. Rietschel ET, Kirikae T, Feist W, Loppnow H, Zabel P, Brade L, Ulmer AJ, Brade H, Seydel U, Zahringer U, Schlaak M, Flad HD, Schade FU: Molecular aspects of the chemistry and biology of endotoxin; in Sies H, Flohe L, Zimmer G (eds): Molecular Aspects of Inflammation (42. Colloquium Mosbach, 1991). Berlin, Springer, 1991, pp 207-231.
34. Loppnow H, Brade L, Brade H, Rietschel ET, Kusumoto S, Shiba T, Flad HD: Induction of human interleukin 1 by bacterial and synthetic lipid A. Eur J Immunol 1986;16:1263-1267.
35. Kovach NL, Yee E, Munford RS, Raetz CR, Harlan JM: Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo. J Exp Med 1990;172:77-84.
36. Loppnow H, Libby P: Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990;85:731-738.
37. Qureshi N, Takayama K, Kurtz R: Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect Immun 1991;59:441-444.
38. Wang M-H, Flad H-D, Feist W, Brade H, Kusumoto S, Rietschel ET, Ulmer AJ: Inhibition of endotoxin-induced interleukin-6 production by synthetic lipid A structures in human peripheral blood mononuclear cells. Infect Immun 1991;59:4655-4664.
39. Christ WJ, Asano O, Robidoux AL, Perez M, Wang Y, Dubuc GR, Gavin WE, Hawkins LD, McGuinness PD, Mullarkey MA: E5531, a pure endotoxin antagonist of high potency. Science 1995;268:80-83.
40. Kitchens RL, Munford RS: Enzymatically deacylated lipopolysaccharide (LPS) can antagonize LPS at multiple sites in the LPS recognition pathway. J Biol Chem 1995;270:9904-9910.
41. Kitchens RL, Ulevitch RJ, Munford RS: Lipopolysaccharide (LPS) partial structures inhibit responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD14-mediated pathway. J Exp Med 1992;176:485-494.
42. Galanos C, Lehmann V, Luderitz O, Rietschel ET, Westphal O, Brade H, Brade L, Freudenberg MA, Hansen-Hagge T, Luderitz T: Endotoxic properties of chemically synthesized lipid A part structures: Comparison of synthetic lipid A precursor and synthetic analogues with biosynthetic lipid A precursor and free lipid A. Eur J Biochem 1984;140:221-227.
43. Kirikae T, Schade FU, Zahringer U, Kirikae F, Brade H, Kusumoto S, Kusama T, Rietschel ET: The significance of the hydrophilic backbone and the hydrophobic fatty acid regions of lipid A for macrophage binding and cytokine induction. FEMS Immunol Med Microbiol 1994; 8:13-26.
44. Delude RL, Savedra RJ, Zhao H, Thieringer R, Yamamoto S, Fenton MJ, Golenbock DT: CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition. Proc Natl Acad Sci USA 1995;92:9288-9292.
45. Wang M-H, Flad H-D, Feist W, Musehold J, Kusumoto S, Brade H, Gerdes J, Rietschel ETh, Ulmer AJ: Inhibition of endotoxin or lipid A-induced tumor necrosis factor production by synthetic lipid A partial structures in human peripheral blood mononuclear cells. Lymphokine Cytokine Res 1992;11:23-31.
46. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR: Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 1991;266: 19490-19498.
47. Saitoh S, Akashi S, Yamada T, Tanimura N, Kobayashi M, Konno K, Matsumoto F, Fukase K, Kusumoto S, Nagai Y, Kusumoto Y, Kosugi A, Miyake K: Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol 2004;16:961-969.
48. Seydel U, Hawkins L, Schromm AB, Heine H, Scheel O, Koch MH, Brandenburg K: The generalized endotoxic principle. Eur J Immunol 2003;33:1586-1592.
49. Schromm AB, Brandenburg K, Loppnow H, Moran AP, Koch MH, Rietschel ET, Seydel U: Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem 2000;267:2008-2013.
50. Heine H, el Samalouti VT, Notzel C, Pfeiffer A, Lentschat A, Kusumoto S, Schmitz G, Hamann L, Ulmer AJ: CD55/decay accelerating factor is part of the lipopolysaccharide-induced receptor complex. Eur J Immunol 2003;33:1399-1408.
51. Ingalls RR, Golenbock DT: CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med 1995;181:1473-1479.
52. Malzan A, Nötzel C, Orinska Z, Bulfone-Paus S, Brade L, Ulmer AJ, Heine H: CD81 deficient mice are protected from LPS-induced shock. J Endotox Res 2002;8:198.
53. Triantafilou M, Brandenburg K, Kusumoto S, Fukase K, Mackie A, Seydel U, Triantafilou K: Combinational clustering of receptors following stimulation by bacterial products determines lipopolysaccharide responses. Biochem J 2004;381:527-536.
54. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M: Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000;275:2251-2254.
55. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000;1:398-401.
56. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, Kurt-Jones E, Paton JC, Wessels MR, Golenbock DT: Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003;100:1966-1971.
57. Gao B, Tsan MF: Endotoxin contamination in recombinant human Hsp70 preparation is responsible for the inducation of TNFalpha release by murine macrophages. J Biol Chem 2003;278: 22523-22529.
58. Tsan MF, Gao B: Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004;76:514-519.
59. Hirschfeld M, Kirschning CJ, Schwandner R, Wesche H, Weis JH, Wooten RM, Weis JJ: Cutting edge: Inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999;163:2382-2386.
60. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, Carroll JD, Espevik T, Ingalls RR, Radolf JD, Golenbock DT: Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999;274:33419-33425.
61. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ: Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274: 17406-17409.
62. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D: Cutting edge: Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999;163:1-5.
63. Opitz B, Schroder NW, Spreitzer I, Michelsen KS, Kirschning CJ, Hallatschek W, Zahringer U, Hartung T, Gobel UB, Schumann RR: Toll-like receptor (TLR)-2 mediates treponema glycolipid and lipoteichoic acid (LTA)-induced NF-kappa B translocation. J Biol Chem 2001;276: 22041-22047.
64. Werts C, Tapping RI, Mathison JC, Chuang TH, Kravchenko V, Saint G, Haake DA, Godowski PJ, Hayashi F, Ozinsky A, Underhill DM, Kirschning CJ, Wagner H, Aderem A, Tobias PS, Ulevitch RJ: Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol 2001;2:346-352.
65. Hirschfeld M, Weis JJ, Toshchakov V, Salkowski CA, Cody MJ, Ward DC, Qureshi N, Michalek SM, Vogel SN: Signaling by Toll-Like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 2001;69:1477-1482.
66. Girard R, Pedron T, Uematsu S, Balloy V, Chignard M, Akira S, Chaby R: Lipopolysaccharides from Legionella and Rhizobium stimulate mouse bone marrow granulocytes via Toll-like receptor 2. J Cell Sci 2003;116:293-302.
67. Spohn R, Buwitt-Beckmann U, Brock R, Jung G, Ulmer AJ, Wiesmuller KH: Synthetic lipopeptide adjuvants and Toll-like receptor 2-structure-activity relationships. Vaccine 2004;22:2494-2499.
68. Wiesmuller KH, Bessler WG, Jung G: Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response. Int J Pept Protein Res 1992;40:255-260.
69. Mühlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G: Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997;185:1951-1958.
70. Metzger JW, Beck-Sickinger AG, Loleit M, Eckert M, Bessler WG, Jung G: Synthetic S-(2,3-dihydroxypropyl)-cysteinyl peptides derived from the N-terminus of the cytochrome subunit of the photoreaction centre of Rhodopseudomonas viridis enhance murine splenocyte proliferation. J Pept Sci 1995;1:184-190.
71. Braun V: Covalent lipoprotein from the outer membrane of Escherichia coli. Biochim Biophys Acta 1975;415:335-377.
72. Metzger J, Wiesmuller KH, Schaude R, Bessler WG, Jung G: Synthesis of novel immunologically active tripalmitoyl-S-glycerylcysteinyl lipopeptides as useful intermediates for immunogen preparations. Int J Pept Protein Res 1991;37:46-57.
73. Ozinsky A, Underbill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A: The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000;97:13766-13771.
74. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S: Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001;13:933-940.
75. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E, Flavell RA: Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002;8:878-884.
76. Morr M, Takeuchi O, Akira S, Simon MM, Muhlradt PF: Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol 2002;32:3337-3347.
77. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S: Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002;169:10-14.
78. Akira S: Mammalian Toll-like receptors. Curr Opin Immunol 2003;15:5-11
79. (published erratum Curr Opin Immunol 2003;15:238).
80. Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Akira S, Ulmer AJ: Toll-like receptor 6-independent signaling of diacylated lipopeptides. Eur J Immunol 2005;35:282-289.
81. Grabiec A, Meng G, Fichte S, Bessler W, Wagner H, Kirschning CJ: Human but not murine toll-like receptor 2 discriminates between tri-palmitoylated and tri-lauroylated peptides. J Biol Chem 2004;279:48004-48012.
82. Bhakdi S, Klonisch T, Nuber P, Fischer W: Stimulation of monokine production by lipoteichoic acids. Infect Immun 1991;59:4614-4620.
83. Greenberg JW, Fischer W, Joiner KA: Influence of lipoteichoic acid structure on recognition by the macrophage scavenger receptor. Infect Immun 1996;64:3318-3325.
84. Fischer W, Mannsfeld T, Hagen G: On the basic structure of poly(glycerophosphate) lipoteichoic acids. Biochem Cell Biol 1990;68:33-43.
85. Behr T, Fischer W, Peter-Katalinic J, Egge H: The structure of pneumococcal lipoteichoic acid. Improved preparation, chemical and mass spectrometric studies. Eur J Biochem 1992;207: 1063-1075.
86. Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U, Gobel UB, Weber JR, Schumann RR: Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003;278:15587-15594.
87. Morath S, Geyer A, Spreitzer I, Hermann C, Hartung T: Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect Immun 2002;70:938-944.
88. Deininger S, Stadelmaier A, von Aulock S, Morath S, Schmidt RR, Hartung T: Definition of structural prerequisites for lipoteichoic acid-inducible cytokine induction by synthetic derivatives. J Immunol 2003;170:4134-4138.
89. Han SH, Kim JH, Martin M, Michalek SM, Nahm MH: Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect Immun 2003;71:5541-5548.
90. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori MA, Werts C, Boneca IG: Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 2004;5:1000-1006.
91. Girardin SE, Philpott DJ: Mini-review: The role of peptidoglycan recognition in innate immunity. Eur J Immunol 2004;34:1777-1782.
92. Lazarus R, Raby BA, Lange C, Silverman EK, Kwiatkowski DJ, Vercelli D, Klimecki WJ, Martinez FD, Weiss ST: TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples. Am J Respir Crit Care Med 2004;170:594-600.
93. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-1103.
94. Samatey FA, Imada K, Nagashima S, Vonderviszt F, Kumasaka T, Yamamoto M, Namba K: Structure of the bacterial flagellar protofilament and implications for a switch for supercoiling. Nature 2001;410:331-337.
95. Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, Cookson BT, Aderem A: Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003;4:1247-1253.
96. Donnelly MA, Steiner TS: Two nonadjacent regions in enteroaggregative Escherichia coli flagellin are required for activation of toll-like receptor 5. J Biol Chem 2002;277:40456-40461.
97. Mizel SB, West AP, Hantgan RR: Identification of a sequence in human toll-like receptor 5 required for the binding of gram-negative flagellin. J Biol Chem 2003;278:23624-23629.
98. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, Ghosh S: A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004;303:1522-1526.
99. Hawn TR, Verbon A, Lettinga KD, Zhao LP, Li SS, Laws RJ, Skerrett SJ, Beutler B, Schroeder L, Nachman A, Ozinsky A, Smith KD, Aderem A: A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med 2003;198:1563-1572.
100. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738.
101. Funami K, Matsumoto M, Oshiumi H, Akazawa T, Yamamoto A, Seya T: The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. Int Immunol 2004;16:1143-1154.
102. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D: mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004;279:12542-12550.
103. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
104. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002;3:499.
105. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E, Cottam HB: Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003;100:6646-6651.
106. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, Dietrich H, Lipford G, Takeda K, Akira S, Wagner H, Bauer S: The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003;33:2987-2997.
107. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA: Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004;101:5598-5603.
108. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-1531.
109. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-1529.
110. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 2000;408: 740-745.
111. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-9242.
112. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002;32:1958-1968.
113. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004;5:190-198.
114. Nishiya T, DeFranco AL: Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004;279: 19008-19017.
115. Wyllie DH, Kiss-Toth E, Visintin A, Smith SC, Boussouf S, Segal DM, Duff GW, Dower SK: Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses. J Immunol 2000;165:7125-7132.
116. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-451.
117. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A: The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens [see comments]. Nature 1999;401:811-815.
118. Flo TH, Halaas O, Lien E, Ryan L, Teti G, Golenbock DT, Sundan A, Espevik T: Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol 2000;164:2064-2069.
119. Takeuchi O, Hoshino K, Akira S: Cutting edge: TLR_2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000;165:5392-5396.
120. Wooten RM, Ma Y, Yoder RA, Brown JP, Weis JH, Zachary JF, Kirschning CJ, Weis JJ: Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol 2002;168:348-355.
121. Underhill DM, Ozinsky A, Smith KD, Aderem A: Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci USA 1999;96: 14459-14463.
122. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ: Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999;163: 3920-3927.
123. Brightbill HD, Library DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, Maitland M, Norgard MV, Plevy SE, Smale ST, Brennan PJ, Bloom BR, Godowski PJ, Modlin RL: Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285: 732-736.
124. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A: Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999;285:736-739.
125. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Muhlradt PF, Akira S: Cutting edge: Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like recept. J Immunol 2000;164:554-557.
126. Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T: Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different toll-like receptors independent of paracrine mediators. J Immunol 2001;166:5161-5167.
127. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT, Fenton MJ: The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol 1999;163:6748-6755.
128. Hashimoto M, Imamura Y, Morichika T, Arimoto K, Takeuchi O, Takeda K, Akira S, Aoyama K, Tamura T, Kotani S, Suda Y, Kusumoto S: Cytokine-inducing macromolecular glycolipids from Enterococcus hirae: Improved method for separation and analysis of its effects on cellular activation. Biochem Biophys Res Commun 2000;273:164-169.
129. Schroder NW, Opitz B, Lamping N, Michelsen KS, Zahringer U, Gobel UB, Schumann RR: Involvement of lipopolysaccharide binding protein, CD14, and Toll-like receptors in the initiation of innate immune responses by Treponema glycolipids. J Immunol 2000;165: 2683-2693.
130. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T: Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: Involvement of Toll-like receptors. Infect Immun 2000;68:6883-6890.
131. Ingalls RR, Lien E, Golenbock DT: Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through toll-like receptor 2. Infect Immun 2001;69:2230-2236.
132. Pridmore AC, Wyllie DH, Abdillahi F, Steeghs L, van Der LP, Dower SK, Read RC: A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via Toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis 2001;183:89-96.
133. Hajjar AM, O'Mahony DS, Ozinsky A, Underhill DM, Aderem A, Klebanoff SJ, Wilson CB: Cutting edge: Functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 2001;166:15-19.
134. Sugawara S, Yang S, Iki K, Hatakeyama J, Tamai R, Takeuchi O, Akashi S, Espevik T, Akira S, Takada H: Monocytic cell activation by nonendotoxic glycoprotein from Prevotella intermedia ATCC 25611 is mediated by Toll-like receptor 2. Infect Immun 2001;69:4951-4957.
135. Campos MA, Almeida IC, Takeuchi O, Akira S, Valente EP, Procopio DO, Travassos LR, Smith JA, Golenbock DT, Gazzinelli RT: Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol 2001;167:416-423.
136. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, Fenton MJ: Different Toll-like receptor agonists induce distinct macrophage responses. J Leukoc Biol 2001;69: 1036-1044.
137. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Hacker H, Wagner H: Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001;276:31332-31339.
138. Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, Ouaaz F, Medzhitov RM, Beg AA: An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001;166:7128-7135.
139. Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, Wagner H, Kirschning CJ, Ter M, Schneider-Schaulies S: Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 2002;76:8729-8736.
140. Ogawa T, Asai Y, Hashimoto M, Uchida H: Bacterial fimbriae activate human peripheral blood monocytes utilizing TLR2, CD14 and CD11a/CD18 as cellular receptors. Eur J Immunol 2002; 32:2543-2550.
141. Flo TH, Ryan L, Latz E, Takeuchi O, Monks BG, Lien E, Halaas O, Akira S, Skjak-Braek G, Golenbock DT, Espevik T: Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem 2002;277:35489-35495.
142. Henneke P, Takeuchi O, van Strijp JA, Guttormsen HK, Smith JA, Schromm AB, Espevik TA, Akira S, Nizet V, Kasper DL, Golenbock DT: Novel engagement of CD14 and multiple toll-like receptors by group B streptococci. J Immunol 2001;167:7069-7076.
143. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM: Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem 2002;277:39320-39326.
144. Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 2002;196:1017-1024.
145. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998;282:2085-2088.
146. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J, Golenbock DT, Vogel SN, Fenton MJ: Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol 2001;166:4074-4082.
147. Qureshi ST, Larivi, Leveque G, Clermont S, Moore KJ, Gros P, Malo D: Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999;189:615-625.
148. Lien E, Chow JC, Hawkins LD, McGuinness PD, Miyake K, Espevik T, Gusovsky F, Golenbock DT: A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/Toll-like receptor 4 signaling pathway. J Biol Chem 2001;276:1873-1880.
149. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M: Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res 2001;7:232-236.
150. Perera PY, Mayadas TN, Takeuchi O, Akira S, Zaks-Zilberman M, Goyert SM, Vogel SN: CD11b/CD18 acts in concert with CD14 and toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 2001;166:574-581.
151. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA: Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 2001;75: 10730-10737.
152. Ohashi K, Burkart V, Flohe S, Kolb H: Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000;164:558-561.
153. Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OF, Espevik T, Sundan A: Inflammatory response after open heart surgery: Release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002;105:685-690.
154. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF: The extra domain A of fibronectin activates toll-like receptor 4. J Biol Chem 2001;276:10229-10233.
155. Smiley ST, King JA, Hancock WW: Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001;167:2887-2894.
156. Lee JY, Sohn KH, Rhee SH, Hwang D: Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001;276:16683-16689.
157. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM: Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 2001;166:4620-4626.
158. Wang JE, Warris A, Ellingsen EA, Jorgensen PF, Flo TH, Espevik T, Solberg R, Verweij PE, Aasen AO: Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun 2001;69:2402-2406.
159. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL: Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2 and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003;278:1561-1568.
160. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M: Cutting edge: The immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002;168:5989-5992.
161. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002;298:1025-1029.
162. Johnson GB, Brunn GJ, Kodaira Y, Platt JL: Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002;168:5233-5239.
163. Rassa JC, Meyers JL, Zhang Y, Kudaravalli R, Ross SR: Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci USA 2002;99:2281-2286.
164. Bulut Y, Faure E, Thomas L, Equils O, Arditi M: Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol 2001;167:987-994.
165. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM: Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001; 167:3555-3558.